Singapore markets close in 3 hours 49 minutes

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
46.78+1.73 (+3.84%)
At close: 04:00PM EDT
47.75 +0.97 (+2.07%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close45.05
Open45.61
Bid46.76 x 200
Ask46.87 x 200
Day's range44.84 - 46.96
52-week range15.76 - 49.58
Volume588,453
Avg. volume814,470
Market cap3.684B
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 9th @ 4:30 PM ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID: 71864759 Participa

  • GlobeNewswire

    Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m

  • GlobeNewswire

    Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

    56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a Conference Call Today at 8:30 a.m. Eastern Time SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercializati